Future Science Group
Supplementrary figures.docx (3.99 MB)

IMT-2021-0145 Supplementary Figures

Download (3.99 MB)
posted on 2021-08-04, 10:47 authored by Figshare Future Science GroupFigshare Future Science Group, Xinke Zhang, Richard W. DeClue, Lisa Herms, Mo Yang, Vivek Pawar, Elizabeth T. Masters, Mary Ruisi, Kevin Chin, Vamsidhar Velcheti

Supplementary Figure 1. Adjusted treatment outcomes including (A) OS, (B) PFS, (C) TTD, and (D) DOR* in the overall population (≥1% PD-L1 expression; N=484).

Supplementary Figure 2. Adjusted treatment outcomes, including (A) OS, (B) PFS, (C) TTD, and (D) DOR* in the low-to-moderate PD-L1 subgroup (1%-49% PD-L1 expression; N=183).

Supplemental Figure 3. Adjusted treatment outcomes, including (A) OS, (B) PFS, (C) TTD, and (D) DOR* in the high PD-L1 subgroup (≥50% PD-L1 expression; N=301).

Real-world treatment patterns and outcomes in PD-L1–positive non-small cell lung cancer


We report real-world treatment patterns and outcomes in patients with PD-L1+ NSCLC.


This retrospective, observational study using the ConcertAI Oncology Dataset, included patients with PD-L1+ (≥1% expression) metastatic NSCLC who began first-line (1L) treatment between 2016-2019. Treatment outcomes were assessed by treatment class (immune checkpoint inhibitor [ICI] monotherapy, ICI combinations, or chemotherapy).


In total, 128 (25.5%), 237 (47.3%) and 136 patients (27.1%) received 1L chemotherapy, 1L ICI monotherapy, and 1L ICI combinations, respectively. ICI combinations and monotherapy had improved clinical outcomes vs chemotherapy. Adjusted analyses showed no significant difference in outcome between ICI monotherapy and ICI combinations.


ICI-based treatments are being increasingly adopted into clinical practice and were associated with better outcomes vs chemotherapy.


Merck KGaA, Darmstadt, Germany